[HCA] HCA Healthcare: Q3 2026 earnings preview as uninsured patients test hospital margins

HCA Healthcare is the largest for-profit hospital operator in the United States, with 190 hospitals and roughly 2,600 outpatient sites across 19 states and England and 2025 revenue of $75.600 billion[1][2]. This HCA Healthcare Q3 2026 earnings preview is anchored on the call scheduled for 2026-10-23, when the company reports results for the third quarter of 2026, ending September 30, 2026[3]. In the most recent disclosed period, the second quarter of 2026, revenue rose 8.7% to $20.230 billion, net income attributable to HCA rose 2.8% to $1.699 billion, diluted EPS rose 11.6% to $7.62, adjusted EBITDA rose 4.6% to $4.027 billion with the margin slipping from 20.7% to 19.9%, and operating cash flow was $2.335 billion, almost half the $4.210 billion of a year earlier[4]. Same facility equivalent admissions grew 2.7% and emergency room visits grew 3.6%, but inpatient surgeries fell 2.3% and outpatient surgeries fell 3.4%[5]. The quarter carried two large policy items pulling in opposite directions: a pre-tax hit of roughly $400 million from exchange patients who lost coverage and became uninsured, and roughly $400 million of incremental net benefit from Medicaid supplemental payments after CMS approved the Florida directed payment program[6]. On July 14 the company lowered its 2026 guidance to revenue of $77.0-79.5 billion, net income attributable to HCA of $6.300-6.700 billion, adjusted EBITDA of $15.4-16.1 billion and diluted EPS of $28.70-30.50, with capital expenditures unchanged at $5.0-5.5 billion[7]; at the same time it raised its full-year assumption for the pre-tax impact of exchange payer mix from ($600)-($900) million to ($1.000)-($1.200) billion and changed its assumption for the incremental net benefit from Medicaid supplemental payment programs from ($50)-($250) million to +$300-500 million[8]. On the July 24 call management added that the $300-500 million full-year supplemental payment benefit implies a $100-300 million headwind in the second half, that fourth-quarter adjusted EBITDA growth should be higher than third-quarter growth, and that the full-year volume growth assumption stays at 2%-3%[9]. The Drillr earnings calendar, updated 2026-09-22, carries third-quarter consensus of EPS $6.735 and revenue $19.406 billion; for reference, second-quarter adjusted EPS of $7.59 compared with an estimate of $7.579, and first-quarter EPS of $7.15 compared with $7.138[10].

Three things in the third-quarter results deserve attention. First, whether the hit from exchange patients turning uninsured narrows or widens: the company estimated a pre-tax impact of roughly $400 million in the second quarter, of which about $75 million was a catch-up on its first-quarter estimate, and same facility uninsured admissions grew 23.4% year over year, accelerating from 15.5% in the first quarter[6][11]; if the third-quarter hit is still $400 million or more, the top of the ($1.000)-($1.200) billion full-year assumption comes under strain. Second, how the income statement and the cash flow statement each behave once Medicaid supplemental payments flip from tailwind to headwind: in the second quarter the Medicaid revenue share jumped from 7.7% to 13.8% and other operating expenses rose from 20.4% to 24.9% of revenue, both fingerprints of the retroactive Florida recognition[12][13], while first-half operating cash flow of $4.349 billion was $1.512 billion below a year earlier, mainly because receivables from Medicaid programs grew[14]; whether the third quarter shows the revenue share falling back and the cash coming in tests whether this policy revenue is only a timing gap. Third, the underlying operation once the policy variables are stripped out: same facility equivalent admissions grew 2.7% and insured volume excluding exchanges grew 3.2% in the second quarter, but inpatient elective surgeries were down 6% year to date and management gave no recovery timetable; on the cost side, salaries and benefits per equivalent admission fell 0.7% while professional fees grew 8.5%[5][15][13][16]. The third quarter's surgical volumes, revenue per equivalent admission and unit costs decide whether volume growth converts into 4%-6% adjusted EBITDA growth.

Company Background and Business Structure

HCA Healthcare is headquartered in Nashville, Tennessee, was founded in 1968, and is a holding company whose affiliates own and operate hospitals and related health care entities. At December 31, 2025 the company owned and operated 190 hospitals, comprising 179 general acute care hospitals, seven behavioral hospitals and four rehabilitation hospitals, plus 121 freestanding surgery centers and 31 freestanding endoscopy centers, with 50,436 licensed beds and a workforce of about 320,000, of whom roughly 90,000 are part-time or PRN staff[1]. As of March 31, 2026 it operated 189 hospitals and approximately 2,600 ambulatory sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics[17]. For the full year 2025 the company recorded 2,297,065 admissions, 4,107,152 equivalent admissions, 9,946,962 emergency room visits, 545,405 inpatient surgeries and 1,022,812 outpatient surgeries, with a 73% occupancy rate, an average length of stay of 4.8 days, 51 days of revenue in accounts receivable and outpatient revenue at 38% of patient revenue[18].

HCA does not report business segments, so its structure is best read through payers and geography. Revenue by payer in 2025 was managed care and other insurers $36,968 million, or 48.9%; managed Medicare $13,435 million, or 17.8%; traditional Medicare $11,273 million, or 14.9%; traditional Medicaid $5,909 million, or 7.8%; managed Medicaid $3,693 million, or 4.9%; international (England) $1,864 million, or 2.5%; and other, including uninsured patients, $2,458 million, or 3.2%[19]. By admissions, managed care accounted for 32%, managed Medicare 27%, traditional Medicare 19%, managed Medicaid 11%, uninsured 7% and traditional Medicaid 4%; within inpatient revenue, managed care accounted for 43%, traditional Medicare and managed Medicare 20% each and traditional Medicaid 12%[20]. Commercially insured patients are only about one-third of admissions yet contribute almost half of revenue, which is why profit is so sensitive to payer mix.

Geographically the company is heavily concentrated in Florida and Texas. At the end of 2025 it owned and operated 47 hospitals and 27 surgery centers in Florida, whose facilities generated $17.856 billion of 2025 revenue, and 55 hospitals and 38 surgery centers in Texas, whose facilities generated $20.962 billion; together the two states produced 59% of admissions, 51% of revenue and 73% of uninsured admissions[21]. As of June 30, 2026 the two states held 103 hospitals, which produced 58% of admissions, 55% of revenue and 73% of uninsured admissions in the second quarter[22]. These two states are the company's fastest-growing population markets, but they are also Medicaid non-expansion states and hurricane-prone, and several of the risks in this article flow from that.

The company's products are acute inpatient care, emergency care, surgery and diagnostic services; its customers are patients who pay through insurers or government programs; demand is driven by physician orders; and delivery depends on bed, operating room and emergency department capacity. Its growth strategy is to expand within its existing large markets, build comprehensive service lines around cardiology, neurology, oncology, orthopedics and women's services, and provide access through outpatient facilities such as surgery centers, urgent care clinics, freestanding emergency care, imaging centers, home health and hospice[23]. Costs are dominated by salaries and benefits (43.5% of 2025 revenue) and supplies (15.0%), while other operating expenses include contract services, professional fees, repairs and maintenance, rents and leases, insurance and non-income taxes such as state provider taxes[24][13]. State Medicaid directed and supplemental payments are a distinctive policy-driven revenue source, totaling approximately $6.2 billion in 2025; these payments generally require periodic CMS approval or reapproval, and most states fund the non-federal share through provider taxes[25].

Financial History and Current Position

On the annual record, HCA has sustained high single-digit revenue growth for two consecutive years. Revenue rose from $64.968 billion in 2023 to $70.603 billion in 2024, up 8.7%, and to $75.600 billion in 2025, up 7.1%; the 2025 increase came from a 2.9% rise in equivalent admissions and a 4.0% rise in revenue per equivalent admission, while same facility revenue grew 6.6% on a 2.4% rise in equivalent admissions and a 4.1% rise in revenue per equivalent admission[2]. Consolidated admissions grew 2.7% in 2025, inpatient surgeries grew 0.9%, outpatient surgeries declined 0.2% and emergency room visits grew 1.6%; revenue from Medicaid state directed and supplemental payment programs was approximately $6.2 billion, against $5.5 billion in 2024[2].

On costs and cash flow, salaries and benefits were 43.5% of revenue in 2025, down from 44.1% in 2024, with salaries and benefits per equivalent admission up 2.4% and same facility salaries and benefits per full-time equivalent up 3.3%; supplies were 15.0% of revenue, down from 15.2%, with supply cost per equivalent admission up 2.7%, including a 7.0% increase for medical devices driven mainly by cardiovascular technologies[24]. Cash provided by operating activities was $12.636 billion in 2025, up from $10.514 billion in 2024 and $9.431 billion in 2023, and the $2.122 billion increase came mainly from a $1.319 billion increase in net income and $524 million of positive working capital changes; capital expenditures excluding acquisitions were $4.944 billion in 2025, $4.875 billion in 2024 and $4.744 billion in 2023; acquisitions consumed $397 million in 2025; and projects under construction at the end of 2025 needed approximately $7.1 billion more over the next five years[26]. The company declared four quarterly dividends of $0.72 per share in 2025, $2.88 in aggregate, and on January 26, 2026 raised the quarterly dividend to $0.78 per share; at the end of 2025 it had $5.779 billion available under its senior unsecured credit facility and $2.207 billion of commercial paper outstanding[27].

The first quarter of 2026 was held down by seasonality and weather. Revenue was $19.109 billion, up 4.3% from $18.321 billion a year earlier; net income attributable to HCA was $1.620 billion, or $7.15 per diluted share, against $6.45; adjusted EBITDA was $3.802 billion, against $3.733 billion; and operating cash flow rose 22.0% to $2.014 billion. Same facility admissions grew 0.9%, equivalent admissions grew 1.3%, emergency room visits grew only 0.3%, inpatient surgeries fell 0.3%, outpatient surgeries fell 1.7% and revenue per equivalent admission rose 3.1%; respiratory-related admissions were down 42% and respiratory-related emergency room visits down 32%, a January winter storm hurt volumes in certain markets, and these unfavorable impacts were mostly offset by the recognition of certain Medicaid supplemental programs that were not in the initial 2026 guidance[28]. CFO Mike Marks said on the call that the $200 million net benefit from supplemental payments in the first quarter was about $120 million above internal expectations, coming from approval of the grandfathered Georgia program and reinstatement of the Atlas program in Texas, so the company changed its full-year supplemental payment assumption to a decline of $50-250 million while keeping the exchange impact assumption at ($600)-($900) million and the full-year volume growth assumption at 2%-3%[29]. At March 31 the balance sheet held $940 million of cash, $48.023 billion of debt and $61.450 billion of total assets; first-quarter capital expenditures were $1.119 billion, the company repurchased 3.157 million shares for $1.571 billion with $9.179 billion of authorization remaining, and it reaffirmed the guidance issued on January 27[17].

The second quarter of 2026 looked strong on the surface, but its structure was rewritten by two policy items. Revenue rose 8.7% to $20.230 billion, net income attributable to HCA rose 2.8% to $1.699 billion, diluted EPS rose 11.6% to $7.62, adjusted diluted EPS rose 11.0% to $7.59, adjusted EBITDA rose 4.6% to $4.027 billion, and the margin was 19.9% against 20.7% a year earlier; diluted shares fell from 241.911 million to 222.828 million, which is why EPS grew far faster than net income[4]. Revenue included $1.372 billion of incremental revenues and $829 million of other operating expenses from the Florida directed payment program covering October 1, 2024 through June 30, 2026, of which approximately $980 million of revenue and $557 million of expense related to periods before 2026[6]. First-half revenue was $39.339 billion against $36.926 billion a year earlier; net income attributable to HCA was $3.319 billion, or $14.77 per diluted share, against $13.28. At June 30 the balance sheet held $1.013 billion of cash, $49.718 billion of debt and $63.250 billion of total assets; second-quarter capital expenditures were $1.231 billion, the company repurchased 4.752 million shares for $2.064 billion, $7.210 billion of repurchase authorization remained, and $3.086 billion was available under the credit facility[30]. First-half operating cash flow was $4.349 billion against $5.861 billion; first-half capital expenditures excluding acquisitions were $2.350 billion, and projects under construction needed approximately $8.6 billion more over the next five years[14]. In the first half the company repurchased 7.909 million shares at an average price of $447.53, paid $354 million of dividends and added $3.065 billion of net debt; in April it issued $3.000 billion of senior notes due 2031, 2033 and 2036, and in May it repaid $2.500 billion of notes due 2026; first-half interest expense was $1.183 billion against $1.115 billion[31].

Operating Model

HCA's revenue equals equivalent admissions multiplied by revenue per equivalent admission. Equivalent admissions combine inpatient admissions and outpatient activity and totaled 4,107,152 in 2025, up 2.9%[18][2]; their growth comes from population growth in core markets such as Florida and Texas, from new beds and outpatient sites, and from the emergency department as a point of entry. The company has approved $7 billion of capital expenditures over the next three years to add 1,000-1,200 inpatient beds and 250-300 outpatient facilities, adding 10% to overall network capacity; since 2018 inpatient beds have grown from 37,000 to 42,000 and occupancy from 71% to 75%[15]. Revenue per equivalent admission depends on payer mix and service mix: commercial insurers pay the highest prices, Medicare and Medicaid pay government rates, with 2026 Medicare inpatient, outpatient and ambulatory surgery rates each up approximately 2.6%[32], uninsured patients are heavily discounted on historical collection rates, and a higher surgical share lifts unit revenue. State Medicaid directed and supplemental payments are recognized in the quarter CMS approves them, for the whole retroactive period, and are the lumpiest part of revenue[25][6]. The second-quarter equation was: same facility equivalent admissions of 1,035,610, up 2.7%, multiplied by revenue per equivalent admission of $19,391, up 6.4% including the Florida catch-up, giving revenue of $20.230 billion, up 8.7%[5][4].

Adjusted EBITDA equals revenue minus salaries and benefits, supplies and other operating expenses, plus equity in earnings of affiliates. In 2025 the three cost lines were 43.5%, 15.0% and the remainder of revenue, with other operating expenses covering contract services, professional fees (anesthesia, radiology), repairs, rents, insurance and state provider taxes[24][13]. In the second quarter of 2026 the three ratios were 41.0%, 14.3% and 24.9%; the first two fell because the Florida catch-up inflated the denominator, while the 4.5-point rise in other operating expenses came mainly from Medicaid directed and supplemental payment program expenses and professional fees; salaries and benefits per equivalent admission fell 0.7%, supply cost per equivalent admission fell 1.0%, and same facility salaries and benefits per full-time equivalent rose 2.5%[13]. Professional fees grew 8.5% year over year and were flat sequentially, with anesthesia and radiology fees still above inflation; management said that after adjusting for Medicaid program impacts, same facility total cost per equivalent admission was flat year over year and improved 1.4% sequentially[16]. The two policy variables in profit run in opposite directions: exchange patients turning uninsured swap commercial prices for charity care and implicit price concessions, a pre-tax hit of roughly $400 million in the second quarter, while approval of the Florida directed payment program delivered a one-time net benefit of roughly $400 million[6]. Further down, second-quarter depreciation and amortization was $944 million against $863 million, and equity in earnings of affiliates was $16 million[13]; after interest and taxes, net income attributable to HCA was $1.699 billion, which divided by 222.828 million diluted shares gives EPS of $7.62[4].

Operating cash flow equals adjusted EBITDA minus interest and income taxes, plus or minus working capital movements, minus distributions to noncontrolling interests. Operating cash flow was $12.636 billion in 2025 and capital expenditures were $4.944 billion, with the remainder funding repurchases and the $2.88 per share dividend[26][27]. In the first half of 2026 operating cash flow was $4.349 billion, $1.512 billion below a year earlier, including $1.099 billion of unfavorable working capital changes driven by higher receivables from Medicaid directed and supplemental payment programs and $579 million of additional income taxes paid after the 2025 IRS deferral of quarterly estimated payments for Tennessee-based taxpayers to the fourth quarter of 2025; second-quarter operating cash flow alone was $2.335 billion, $1.875 billion below the $4.210 billion of a year earlier, with $1.413 billion of unfavorable working capital changes[14]. This means most of the Florida benefit recognized in the second-quarter income statement is still sitting in receivables. On the financing side, the first half saw $3.635 billion of repurchases, $354 million of dividends and $334 million of distributions to noncontrolling interests, with net debt up $3.065 billion, debt of $49.718 billion at the end of June and $7.210 billion of repurchase authorization remaining[31]; the company plans to complete nearly all of the existing authorization by year end, and 2026 capital expenditure guidance stays at $5.0-5.5 billion[9].

Industry and Competitive Position

The US hospital industry is a set of localized and highly competitive markets, and HCA's rivals vary by market. The company writes in its annual report that other hospitals in the communities it serves provide similar services and that the number of freestanding specialty hospitals, surgery centers, emergency departments, urgent care centers, diagnostic and imaging centers continues to increase; some competing facilities are physician-owned or tax-supported, and many more are not-for-profit entities supported by endowments, charitable contributions and tax exemptions, advantages that work against HCA in funding capital expenditures; certain localities also have large teaching hospitals offering highly specialized services that most HCA hospitals do not, and in high-margin services the company competes with both its own and unaffiliated freestanding surgery centers[33].

HCA's evidenced advantages are scale and network integration. Management said on the second-quarter call that competitive positioning is "stable to improving" overall, with market share gains in most markets, supported by favorable demographic growth in its core southeastern and southwestern markets, and that total care sites were up 5% year over year[15]. The enterprise-wide financial resiliency program leverages digital transformation, global shared services and workforce development to bend the cost curve, and in the second quarter it held same facility cost per equivalent admission nearly flat year over year; the company is an in-network provider for nearly all commercial and exchange plans, with about 85% of exchange and commercial business in network, so its volume of independent dispute resolution under the No Surprises Act is very low[16]. Its growth strategy is to densify networks in existing large markets and improve patient retention through comprehensive service lines and outpatient points of access[23].

The comparison has clear limits. HCA does not disclose segment data or financial data for exchange patients, so the exchange impact, the split between elective and emergency surgery and unit cost excluding Medicaid effects are all management's verbal estimates; many second-quarter ratios cannot be compared year over year because of the Florida catch-up. The whole industry faces the same policy environment: the enhanced premium tax credits expired at the end of 2025, and the annual report states plainly that their expiration is expected to reduce exchange enrollment and increase the uninsured rate; the Federal Budget Act (FBA) contains provisions that cut Medicaid spending, impose work requirements on adults in expansion states and limit some Medicaid financing mechanisms[34]. The forward-looking risk factors listed in the annual report also place changes in payer mix (including increases in uninsured and underinsured patients), reductions in Medicaid supplemental payments and state directed payments, and the collectability of uninsured accounts and deductibles near the top[35].

Core Debates

With nearly every patient who lost exchange coverage turning uninsured, does the roughly $400 million quarterly hit narrow in the third quarter or keep widening?

This debate matters because it is the sole reason guidance was cut on July 14. The company raised its full-year assumption for the pre-tax impact of exchange payer mix from ($600)-($900) million to ($1.000)-($1.200) billion, and net income guidance fell from $6.495-7.035 billion to $6.300-6.700 billion[8][7]. Managed care and insurers are HCA's largest payer, at 48.9% of 2025 revenue[19]; exchange patients are about 6.8% of equivalent admissions, and every one who becomes uninsured converts a commercial price into charity care or an implicit price concession[36]. Florida and Texas account for 73% of the company's uninsured admissions and are non-expansion states[21], and three divisions, Gulf Coast, North Florida and South Atlantic, accounted for half of the overall impact, with composite exchange adjusted admission declines of 25%-28% year to date[36].

The current evidence shows the hit still accelerating in the second quarter. The company estimated that the payer mix shift reduced income before income taxes by approximately $400 million, including an increase of approximately $75 million related to its previous estimate of the first-quarter impact[6]; same facility uninsured admissions rose 23.4% year over year, against 15.5% in the first quarter, and the four quarters of 2025 showed a 0.7% decline, a 0.4% increase, a 2.0% decline and a 7.1% increase, with the 10-Q attributing the increases to the expiration of the enhanced premium tax credits, administrative reforms and a decline in Medicaid conversions[11]. Total uncompensated care rose from $11.625 billion to $15.076 billion, and its estimated cost from $1.116 billion to $1.445 billion[37]; managed care and insurer revenue was $9,013 million, down 1.2%, with its share falling from 49.1% to 44.6%[12]. Management said the original assumption of a 15% decline in exchange volume was correct and the error was the destination: it had assumed 80%-85% of patients losing coverage would become uninsured, and the actual shift was nearly one-for-one; uninsured volume is now just over 10% of equivalent admissions, the combined share of exchange and uninsured is unchanged year over year, confirming the one-for-one migration, and 80% of uninsured volume growth comes from exchange migration with the remaining 20% from a slowdown in Medicaid conversions concentrated in Texas[36].

The two readings diverge here. The optimistic reading holds that the loss is a one-time stock migration in 2026: the fourth-quarter comparison is easier because exchange growth slowed unexpectedly in the fourth quarter of 2025 after late-year policy changes, so pressure eases sequentially, and management estimates that coverage losses from the expired credits will be "substantially lower" in 2027 than in 2026, assuming no new enhanced premium support[36]. The cautious reading points out that the impact estimate was already revised up once between the first and second quarters, uninsured growth was still accelerating in the second quarter, and the continuing effects of administrative reforms and the FBA on the exchanges are not yet fully in the numbers[11][34]; if the third-quarter hit is still above $400 million, even the $1.2 billion ceiling does not hold. No evidence yet settles which reading is right.

The third quarter comes down to three numbers. First, whether the disclosed quarterly exchange payer mix impact falls back below $300 million and whether the ($1.000)-($1.200) billion full-year range moves again; second, whether same facility uninsured admissions in the 10-Q come back from the 23.4% level to within +25% and whether the estimated cost of uncompensated care stays within $1.5 billion; third, whether exchange patients hold at 6.5% or more of equivalent admissions and whether management keeps describing 2027 as "substantially lower than 2026." Conversely, a third-quarter hit of $400 million or more, or another upward revision of the full-year range, confirms the cautious reading; a fall in same facility uninsured admission growth below 15% together with a cut in the full-year impact range falsifies this debate's negative hypothesis.

Was the second quarter's $400 million Medicaid supplemental net benefit a one-time catch-up, and does the third quarter flip to the guided headwind while the Florida receivable turns into cash?

State directed and supplemental payments are the least transparent and most policy-dependent line in HCA's income statement. Related revenue was approximately $6.2 billion in 2025, $5.5 billion in 2024 and $4.4 billion in 2023, yet the annual report states that these payments plus Medicaid base rates are generally still insufficient to cover the cost of care for Medicaid beneficiaries after the cost of financing the non-federal share through state or local provider taxes; CMS is limiting pass-through payments under managed Medicaid contracts and will generally prohibit them by July 2027[25]. In the second quarter CMS approved the Florida program and the company recognized $1.372 billion of revenue and $829 million of expense at once, a net benefit of roughly $400 million that almost fully offset the roughly $400 million exchange hit[6], and the full-year supplemental payment assumption flipped from ($50)-($250) million to +$300-500 million, excluding any future approvals[8]. The price was cash: second-quarter operating cash flow was $2.335 billion, $1.875 billion below a year earlier, as receivables rose on Medicaid programs[14]. The third quarter is the first with no known new approval.

The fingerprints of retroactive recognition are all over the second-quarter statements. Traditional Medicaid revenue was $2,789 million, or 13.8%, against $1,440 million, or 7.7%, a year earlier[12]; Medicaid was 20% of inpatient revenue against 12%, and the 10-Q attributes the change in inpatient revenue mix directly to state directed and supplemental payment programs[22]; outpatient revenue fell from 38.4% to 33.7% of patient revenue[5]; other operating expenses were 24.9% of revenue against 20.4%, attributed to program expenses and professional fees[13]. Management broke down on the call that the quarter's $400 million incremental net benefit included $540 million from the newly approved Florida program covering October 1, 2024 through June 30, 2026, partially offset by prior-year retroactive payments; the $300-500 million full-year assumption implies a $100-300 million headwind in the second half, because prior-year retroactive benefits in the second half of 2025 exceed the incremental new Florida benefit in the back half, which is also why fourth-quarter adjusted EBITDA growth should be higher than third-quarter growth[9]. The first quarter's $200 million net benefit came from the Georgia and Texas Atlas programs[29]. First-half operating cash flow was $4.349 billion against $5.861 billion, of which $1.099 billion was working capital and $579 million was the catch-up on deferred Tennessee income taxes[14].

The two readings split on "timing gap" versus "changed normal." One reading holds that this is only timing: Florida pays in the second half, third-quarter operating cash flow returns above $4 billion, and the income-statement headwind stays within guidance. The other reading holds that approval itself is no longer the norm: the FBA is restricting state directed payments and provider tax financing[34], CMS will prohibit managed Medicaid pass-through payments by July 2027[25], every state program has to be reapproved when it expires, and the Florida program itself was approved only nine months after its program year ended[37]; management also listed Medicaid work requirements in non-expansion states, which represent 60% of the company's Medicaid revenue, as a potential source of coverage leakage, with litigation still delaying final implementation[9]. The second-quarter statements cannot separate these two readings.

The third quarter comes down to three sets of numbers. First, whether the quarterly incremental net benefit lands between -$50 million and -$150 million, whether the $300-500 million full-year range holds, and whether any new state program is approved; second, whether traditional Medicaid revenue returns to $1.8-2.3 billion and other operating expenses return to 21%-23% of revenue; third, whether operating cash flow returns above $3.8 billion and whether the 10-Q still attributes rising receivables to Medicaid programs. If the third-quarter Medicaid revenue share stays above 13% with no new approval disclosed, or operating cash flow stays below $3.0 billion with receivables still rising, the "timing gap" reading fails.

Emergency and inpatient volumes are growing, elective surgeries are falling and unit costs are flat: does the third quarter net these forces out to 4-6% adjusted EBITDA growth?

Strip away the exchange and Medicaid policy variables and HCA's underlying business is the utilization of beds and outpatient sites in growth markets such as Florida and Texas. In 2025 equivalent admissions grew 2.9%, same facility revenue per equivalent admission grew 4.1% and full-year revenue grew 7.1% to $75.600 billion[2], and adjusted EBITDA follows from that. The company has approved $7 billion of capital expenditures over the next three years to add 1,000-1,200 beds and 250-300 outpatient sites, a 10% capacity increase, and since 2018 beds have grown from 37,000 to 42,000 and occupancy from 71% to 75%[15]. But elective surgery slid in the second quarter, with inpatient elective surgeries down 6% year to date, which J.P. Morgan analyst Benjamin Rossi called "unprecedented for HCA outside of COVID-impacts during 2020 [and] 2021"[38], and that directly erodes the high-margin service lines. The 2025 totals of 545,405 inpatient surgeries and 1,022,812 outpatient surgeries are the annual scale of that service line[18].

The second-quarter operating numbers show volume rising, surgery falling and costs flattened. Same facility equivalent admissions grew 2.7%, admissions grew 2.5% and emergency room visits grew 3.6%; same facility inpatient surgery cases were 132,312, down 2.3%, and outpatient surgery cases were 242,395, down 3.4%; for the first half, same facility equivalent admissions grew 2.0%, inpatient surgeries fell 1.4% and outpatient surgeries fell 2.5%[5]. Management said insured volume excluding exchanges grew 3.2% in the quarter and 2.2% year to date, that emergency room visits, cardiac procedures and rehabilitation drove volume growth, and that emergency inpatient surgery, two-thirds of total inpatient surgeries, grew 2% year over year; it attributed the elective decline to exchange coverage loss, broader affordability pressures and Medicare regulatory shifts that moved cases to outpatient settings, said it is investing in OR optimization and physician alignment, and did not commit to a specific back-half rebound timeline[15]. On costs, salaries and benefits per equivalent admission fell 0.7%, supply cost per equivalent admission fell 1.0%, and same facility salaries and benefits per full-time equivalent rose 2.5%[13]; professional fees grew 8.5%, and after adjusting for Medicaid program impacts, same facility total cost per equivalent admission was flat year over year and improved 1.4% sequentially[16]. Adjusted EBITDA was $4.027 billion, up 4.6%, at a 19.9% margin against 20.7%[4], and the first quarter's same facility equivalent admission growth of only 1.3% and revenue per equivalent admission growth of 3.1% serve as the seasonal comparison[28].

The optimistic reading holds that demand in growing-population markets is structural: emergency, cardiovascular and rehabilitation growth pulls inpatient volume with it, elective surgery partly recovers in the second half once patients meet their deductibles, and the resiliency program keeps cost growth below revenue growth, with management saying the program should deliver improved cost trends in the second half[16]. The cautious reading points out that elective surgery has now declined for two straight years, down 2% in 2025 and 6% in the first half of 2026, and that management itself attributes the decline to coverage loss and affordability while committing to no recovery date[15]; if third-quarter surgical volumes fall another 3% or more while revenue per equivalent admission excluding the catch-up returns below 3%, volume growth is only low-value volume growth. The second quarter's 6.4% growth in revenue per equivalent admission includes the Florida catch-up and cannot serve as a clean reading of pricing power[11].

The third quarter comes down to surgical volume, unit revenue and unit cost. First, whether same facility equivalent admissions hold at +2% to +3.5% and emergency room visits hold at +2% or better; second, whether the year-over-year declines in same facility inpatient and outpatient surgeries narrow to within 2% and whether management gives a first timetable for elective surgery recovery; third, whether salaries and benefits per equivalent admission stay within +1.5%, whether professional fee growth comes down from 8.5%, and whether adjusted EBITDA growth lands between +2% and +6%. If third-quarter equivalent admission growth is below 1.5% and the company cuts its full-year volume assumption, or salaries and benefits per equivalent admission turn to +3% or more with the resiliency program failing to offset professional fee inflation, the optimistic reading of this debate is falsified.

Risks and Falsifiers

The first risk is high leverage combined with the pace of buybacks. Debt was $49.718 billion at June 30, 2026, first-half interest expense was $1.183 billion, and in the same half that operating cash flow fell $1.512 billion the company repurchased $3.635 billion of stock and added $3.065 billion of net debt[31][14]; $7.210 billion of repurchase authorization remains[30], the company plans to use nearly all of it by year end, 2026 capital expenditures are $5.0-5.5 billion[9], and projects under construction need $8.6 billion more[14]. The exposed lines are interest expense, the debt balance and free cash flow: if Florida payments are delayed and the exchange hit continues, buybacks can only be sustained with new debt. The falsifier is third-quarter operating cash flow back above $4 billion, a flat or lower debt balance, and buybacks completed on the authorized pace without a new large debt issue.

The second risk is Florida and Texas concentration. The two states produced 58% of admissions, 55% of revenue and 73% of uninsured admissions in the second quarter[22]; Florida facilities generated $17.856 billion and Texas facilities $20.962 billion of 2025 revenue, across 103 hospitals[21]; both are Medicaid non-expansion states and hurricane-prone, and management noted that Medicaid work requirements would hit non-expansion states harder, which represent 60% of the company's Medicaid revenue[9]. The exposed lines are revenue and uninsured admissions in these two states and hurricane-related volume and cost. The falsifier is a third-quarter 10-Q with no hurricane-related volume or cost disclosure, the two states' share of uninsured admissions holding around 73%, and no acceleration of the Medicaid work requirement timetable.

The third risk is that 2027 exchange losses do not "slow substantially" as management expects. Without new subsidies and with administrative reforms continuing to shrink enrollment, the uninsured share keeps rising. The exposed line is managed care and insurer revenue, $36,968 million or 48.9% in 2025[19], with exchange patients at about 6.8% of equivalent admissions[36] and the company's 2026 pre-tax impact estimate at $1.0-1.2 billion[8]. The falsifier is a narrower year-over-year decline in fourth-quarter exchange volume and a 2027 guidance range for the exchange impact that is clearly below 2026.

The fourth risk is policy tightening on state directed payments. The FBA restricts state directed payments and provider tax financing[34], CMS will prohibit managed Medicaid pass-through payments by July 2027, and state programs may be delayed or reduced when they come up for reapproval[25]. The exposed lines are the approximately $6.2 billion of 2025 revenue from state directed and supplemental payments and the $300-500 million full-year incremental net benefit assumption, which excludes any new approvals[25][9]. The falsifier is approval of the major state programs for the 2026-2027 program years and a third-quarter 10-Q with no new language on cuts or delays.

The fifth risk is a continued slide in elective surgery. Consumer affordability pressure and Medicare policy are pushing cases to outpatient settings, elective surgery has been declining for more than a year, and the share of high-margin service lines keeps falling[15]. The exposed line is surgery-related revenue: 545,405 inpatient and 1,022,812 outpatient surgeries in 2025[18], inpatient elective surgeries down 6% in the first half of 2026, and same facility inpatient surgeries down 2.3% and outpatient surgeries down 3.4% in the second quarter[5]. The falsifier is third-quarter same facility inpatient and outpatient surgery declines both narrowing to within 2%, with revenue per equivalent admission excluding the catch-up still above 3%.

What to Watch Next

The list below compresses the three core debates and the cross-cutting risk into items that can be checked against the third-quarter disclosure, each with its second-quarter 2026 baseline.

• Exchange loss to uninsured, disclosed quarterly pre-tax impact: baseline roughly $400 million, including about $75 million of first-quarter catch-up. Watch whether it falls below $300 million and whether the ($1.000)-($1.200) billion full-year range moves. A hit of $400 million or more, or another upward revision, is negative confirmation.
• Exchange loss to uninsured, same facility uninsured admissions and estimated cost of uncompensated care: baseline +23.4% and $1.445 billion. Watch whether growth stays within +25% and cost within $1.5 billion. A fall below +15% with a cut in the impact range falsifies the negative hypothesis.
• Exchange loss to uninsured, exchange share of equivalent admissions and the 2027 language: baseline 6.8% and "substantially lower than 2026." Watch whether the share holds at 6.5% or above and the language holds. A further slide in the share or weaker language raises the risk.
• Medicaid supplemental payments, quarterly incremental net benefit and new approvals: baseline roughly +$400 million with a +$300-500 million full-year assumption. Watch whether the quarter lands between -$50 million and -$150 million and whether the full-year range holds. A still-elevated share with no new approval defeats the timing-gap reading.
• Medicaid supplemental payments, traditional Medicaid revenue and other operating expenses: baseline $2,789 million, or 13.8%, and 24.9% of revenue. Watch for a return to $1.8-2.3 billion and to 21%-23%. A share still above 13% with no new approval is negative confirmation.
• Medicaid supplemental payments, operating cash flow and receivable attribution: baseline $2.335 billion for the quarter and $4.349 billion for the half. Watch for a return above $3.8 billion and whether the 10-Q still attributes receivables to Medicaid programs. Below $3.0 billion with receivables still rising is negative confirmation.
• Volume, mix and unit cost, same facility equivalent admissions and emergency room visits: baseline +2.7% and +3.6%. Watch for +2% to +3.5% and emergency visits at +2% or better. Below +1.5% with a cut in the full-year volume assumption falsifies the optimistic reading.
• Volume, mix and unit cost, same facility inpatient and outpatient surgeries: baseline -2.3% and -3.4%. Watch whether the declines narrow to within -2% and whether a recovery timetable appears. Continued declines of -3% or worse with unit revenue excluding the catch-up below 3% is negative confirmation.
• Volume, mix and unit cost, salaries and benefits per equivalent admission, professional fees and adjusted EBITDA growth: baseline -0.7%, +8.5% and +4.6%. Watch for salaries and benefits at +1.5% or less, professional fees coming down and adjusted EBITDA growth of +2% to +6%. Salaries and benefits at +3% or more without offsetting professional fee inflation falsifies the optimistic reading.
• Cross-cutting risk, debt, buybacks and issuance: baseline debt of $49.718 billion and $7.210 billion of remaining authorization. Watch whether debt holds flat or falls and whether any new large issue appears. Operating cash flow back above $4 billion with no new large issue eases the risk.

Conclusion

HCA's business is turning the utilization of beds, operating rooms and emergency departments in growth markets such as Florida and Texas into revenue, where revenue equals equivalent admissions multiplied by revenue per equivalent admission, and the margin depends on the share of commercially insured patients and on control of salaries, supplies and professional fees. The base of $75.600 billion of 2025 revenue and $12.636 billion of operating cash flow is solid[2][26], but the second quarter of 2026's $20.230 billion of revenue and $4.027 billion of adjusted EBITDA contain two policy items of roughly $400 million each pulling in opposite directions: the pre-tax hit from exchange patients migrating one-for-one to uninsured, and the one-time retroactive net benefit from the Florida directed payment program[4][6]. The former made the company raise its full-year impact assumption to ($1.000)-($1.200) billion and cut guidance; the latter flipped the full-year supplemental payment assumption to +$300-500 million while leaving $1.875 billion of cash in receivables[8][14]. The third quarter is the first with no known new approval, supplemental payments turn into the guided headwind, and the only remaining offset to the exchange hit is underlying demand, which elective surgery's two-year slide has itself split into high-quality emergency admissions and low-quality volume growth[9][15]. Debt of $49.718 billion and the plan to use nearly all of the $7.210 billion repurchase authorization by year end turn the cash-flow timing gap into a balance-sheet question[31][30].

The two independent commentaries published after the second quarter each stand on a different side of this triangle. Healthcare Dive reporter Rebecca Pifer Parduhn on July 27 characterized the quarter as "almost all of HCA's ACA patients are going uninsured," recording CEO Sam Hazen's words that "essentially all of them" were going uninsured, ACA volumes down 15% while uninsured volumes rose 15%, and a roughly $400 million income hit partially offset by Florida supplemental payments, and relayed two sell-side analysts with opposite emphases: J.P. Morgan's Benjamin Rossi saw the 2.3% inpatient and 4.4% outpatient surgery declines and the 6% first-half elective decline against 2% a year earlier as "unprecedented for HCA outside of COVID-impacts during 2020 [and] 2021," while Leerink Partners' Whit Mayo observed that "operating trends and costs generally look good"[38]. Rossi's comment maps to the cautious reading in the third debate, that the elective decline is structural; Mayo's maps to the optimistic reading, that volume and costs are fine and the problem is only payer mix. MarketBeat's framing on September 17, a month before the event, was "solid demand, exchange headwinds pressure the outlook": insured business excluding exchange plans up 3.2%, adjusted admissions up 2.7%, the $1.0-1.2 billion full-year exchange impact offset by $300-500 million of net state supplemental payments and underlying demand, management still anticipating exchange pressure in 2027 but less severe than in 2026, and a target framework of 4%-6% revenue growth with at least stable margins[39]. All three voices mostly relay company disclosure and none offers an independent forecast; their disagreement is not about facts but about whether "demand offsets the policy hit" is an established conclusion or a hypothesis the third quarter still has to test. Once Medicaid supplemental payments turn into a second-half headwind, the word "offset" rests on demand alone in the third quarter.

The combination that would clearly strengthen the current understanding is a disclosed third-quarter exchange impact back below $300 million and same facility uninsured admission growth coming down from 23.4%, together with the traditional Medicaid revenue share back below 13% and operating cash flow back above $3.8 billion, while same facility equivalent admissions hold above 2%, surgery declines narrow to within 2% and salaries and benefits per equivalent admission stay within 1.5%. The combination that would clearly weaken it is an exchange impact still at $400 million or more with another upward revision of the full-year range, a Medicaid revenue share still above 13% with no new approval, operating cash flow below $3.0 billion with receivables still rising, and surgical volumes falling another 3% or more while revenue per equivalent admission excluding the catch-up returns below 3%. Between those two combinations, the third-quarter statements will most likely deliver a mixed signal, and the key to reading them is to strip the Florida retroactive recognition out of every ratio first.

Sources

[1] HCA 10-K filed 2026-02-10 · company overview and footprint · 2026-02-10 · 10-K · https://www.sec.gov/Archives/edgar/data/860730/000119312526044769/hca-20251231.htm

[2] HCA 10-K filed 2026-02-10 · FY2025 revenue and volume results · 2026-02-10 · 10-K · https://www.sec.gov/Archives/edgar/data/860730/000119312526044769/hca-20251231.htm

[3] Drillr earnings calendar · HCA earnings call scheduled 2026-10-23 (calendar last updated 2026-09-22) · 2026-09-22 · Drillr earnings calendar

[4] HCA 8-K filed 2026-07-24 · 2Q26 results press release · 2026-07-24 · 8-K · https://www.sec.gov/Archives/edgar/data/860730/000119312526315151/hca-ex99_1.htm

[5] HCA 8-K filed 2026-07-24 · 2Q26 same facility volumes and pricing · 2026-07-24 · 8-K · https://www.sec.gov/Archives/edgar/data/860730/000119312526315151/hca-ex99_1.htm

[6] HCA 8-K filed 2026-07-24 · 2Q26 commentary on exchange payer mix and Medicaid supplemental payments · 2026-07-24 · 8-K · https://www.sec.gov/Archives/edgar/data/860730/000119312526315151/hca-ex99_1.htm

[7] HCA 8-K filed 2026-07-14 · 2Q26 preview and revised 2026 guidance · 2026-07-14 · HCA Healthcare · https://www.sec.gov/Archives/edgar/data/860730/000119312526302539/hca-ex99_1.htm

[8] HCA 8-K filed 2026-07-14 · revised 2026 key assumptions: exchanges and Medicaid supplemental payments · 2026-07-14 · HCA Healthcare · https://www.sec.gov/Archives/edgar/data/860730/000119312526302539/hca-ex99_1.htm

[9] HCA 2Q26 earnings call 2026-07-24 · guidance mechanics, Medicaid supplemental timing and policy risks · 2026-07-24 · HCA Healthcare · https://investor.hcahealthcare.com/events-and-presentations/default.aspx

[10] Drillr earnings calendar (updated 2026-09-22) · HCA 2026-10-23 call and 3Q26 estimates · 2026-09-22 · Drillr earning_call_calendar · https://gateway.drillr.ai/mcp/private#earning_call_calendar

[11] HCA 10-Q filed 2026-07-28 · 2Q26 uninsured admissions trend · 2026-07-28 · 10-Q · https://www.sec.gov/Archives/edgar/data/860730/000119312526321077/hca-20260630.htm

[12] HCA 10-Q filed 2026-07-28 · 2Q26 revenues by payer · 2026-07-28 · 10-Q · https://www.sec.gov/Archives/edgar/data/860730/000119312526321077/hca-20260630.htm

[13] HCA 10-Q filed 2026-07-28 · 2Q26 operating expenses · 2026-07-28 · 10-Q · https://www.sec.gov/Archives/edgar/data/860730/000119312526321077/hca-20260630.htm

[14] HCA 10-Q filed 2026-07-28 · 1H26 liquidity and cash flow · 2026-07-28 · 10-Q · https://www.sec.gov/Archives/edgar/data/860730/000119312526321077/hca-20260630.htm

[15] HCA 2Q26 earnings call 2026-07-24 · demand, surgical volumes and capacity plan · 2026-07-24 · earnings-call · https://investor.hcahealthcare.com/events-and-presentations/default.aspx

[16] HCA 2Q26 earnings call 2026-07-24 · cost resiliency program and professional fees · 2026-07-24 · earnings-call · https://investor.hcahealthcare.com/events-and-presentations/default.aspx

[17] HCA 8-K filed 2026-04-24 · 1Q26 balance sheet, buybacks and guidance reaffirmed · 2026-04-24 · 8-K · https://www.sec.gov/Archives/edgar/data/860730/000119312526174933/hca-ex99_1.htm

[18] HCA 10-K filed 2026-02-10 · FY2025 operating statistics · 2026-02-10 · 10-K · https://www.sec.gov/Archives/edgar/data/860730/000119312526044769/hca-20251231.htm

[19] HCA 10-K filed 2026-02-10 · FY2025 revenues by payer · 2026-02-10 · 10-K · https://www.sec.gov/Archives/edgar/data/860730/000119312526044769/hca-20251231.htm

[20] HCA 10-K filed 2026-02-10 · FY2025 admissions by payer · 2026-02-10 · 10-K · https://www.sec.gov/Archives/edgar/data/860730/000119312526044769/hca-20251231.htm

[21] HCA 10-K filed 2026-02-10 · Florida and Texas concentration · 2026-02-10 · 10-K · https://www.sec.gov/Archives/edgar/data/860730/000119312526044769/hca-20251231.htm

[22] HCA 10-Q filed 2026-07-28 · 2Q26 admissions by payer and Florida-Texas concentration · 2026-07-28 · 10-Q · https://www.sec.gov/Archives/edgar/data/860730/000119312526321077/hca-20260630.htm

[23] HCA 10-K filed 2026-02-10 · business strategy and network development · 2026-02-10 · 10-K · https://www.sec.gov/Archives/edgar/data/860730/000119312526044769/hca-20251231.htm

[24] HCA 10-K filed 2026-02-10 · FY2025 operating expense ratios · 2026-02-10 · 10-K · https://www.sec.gov/Archives/edgar/data/860730/000119312526044769/hca-20251231.htm

[25] HCA 10-K filed 2026-02-10 · Medicaid state directed and supplemental payments · 2026-02-10 · 10-K · https://www.sec.gov/Archives/edgar/data/860730/000119312526044769/hca-20251231.htm

[26] HCA 10-K filed 2026-02-10 · FY2025 cash flow and capital expenditures · 2026-02-10 · 10-K · https://www.sec.gov/Archives/edgar/data/860730/000119312526044769/hca-20251231.htm

[27] HCA 10-K filed 2026-02-10 · dividends and credit facility capacity · 2026-02-10 · 10-K · https://www.sec.gov/Archives/edgar/data/860730/000119312526044769/hca-20251231.htm

[28] HCA 8-K filed 2026-04-24 · 1Q26 results and same facility volumes · 2026-04-24 · 8-K · https://www.sec.gov/Archives/edgar/data/860730/000119312526174933/hca-ex99_1.htm

[29] HCA 1Q26 earnings call 2026-04-24 · Medicaid supplemental payments and guidance bridge · 2026-04-24 · earnings-call · https://investor.hcahealthcare.com/events-and-presentations/default.aspx

[30] HCA 8-K filed 2026-07-24 · 2Q26 balance sheet, cash flow and capital returns · 2026-07-24 · 8-K · https://www.sec.gov/Archives/edgar/data/860730/000119312526315151/hca-ex99_1.htm

[31] HCA 10-Q filed 2026-07-28 · 1H26 financing, debt and share repurchases · 2026-07-28 · 10-Q · https://www.sec.gov/Archives/edgar/data/860730/000119312526321077/hca-20260630.htm

[32] HCA 10-K filed 2026-02-10 · Medicare payment rate updates for 2026 · 2026-02-10 · 10-K · https://www.sec.gov/Archives/edgar/data/860730/000119312526044769/hca-20251231.htm

[33] HCA 10-K filed 2026-02-10 · competition · 2026-02-10 · 10-K · https://www.sec.gov/Archives/edgar/data/860730/000119312526044769/hca-20251231.htm

[34] HCA 10-K filed 2026-02-10 · health care public policy: EPTC expiration and the FBA · 2026-02-10 · 10-K · https://www.sec.gov/Archives/edgar/data/860730/000119312526044769/hca-20251231.htm

[35] HCA 10-K filed 2026-02-10 · forward-looking risk factors on payer mix and policy · 2026-02-10 · 10-K · https://www.sec.gov/Archives/edgar/data/860730/000119312526044769/hca-20251231.htm

[36] HCA 2Q26 earnings call 2026-07-24 · exchange coverage loss and uninsured migration · 2026-07-24 · earnings-call · https://investor.hcahealthcare.com/events-and-presentations/default.aspx

[37] HCA 10-Q filed 2026-07-28 · 2Q26 uncompensated care · 2026-07-28 · 10-Q · https://www.sec.gov/Archives/edgar/data/860730/000119312526321077/hca-20260630.htm

[38] Healthcare Dive 2026-07-27 · Almost all of HCA's Affordable Care Act patients are going uninsured. Here's how that affected Q2 · 2026-07-27 · Healthcare Dive · https://www.healthcaredive.com/news/hca-healthcare-q2-2026-aca-patients-uninsured-surgeries/826113/

[39] MarketBeat 2026-09-17 · HCA Healthcare Sees Solid Demand as Exchange Headwinds Pressure 2026 Outlook · 2026-09-17 · MarketBeat · https://finance.yahoo.com/healthcare/articles/hca-healthcare-sees-solid-demand-030202250.html